• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Rev Clin Esp (Barc) . CURB-65 as a predictor of 30-day mortality in patients hospitalized with COVID-19 in Ecuador: COVID-EC study

tetano

Editor, Senior Moderator
Rev Clin Esp (Barc)


. 2022 Jan;222(1):37-41.
doi: 10.1016/j.rceng.2020.10.006. Epub 2021 Apr 30.
CURB-65 as a predictor of 30-day mortality in patients hospitalized with COVID-19 in Ecuador: COVID-EC study


J Carriel[SUP] 1 [/SUP], R Muñoz-Jaramillo[SUP] 2 [/SUP], O Bolaños-Ladinez[SUP] 3 [/SUP], F Heredia-Villacreses[SUP] 3 [/SUP], J Menéndez-Sanchón[SUP] 4 [/SUP], J Martin-Delgado[SUP] 5 [/SUP], COVID-EC Researh Group



Affiliations

Abstract

Objective: This article aims to assess the utility of CURB-65 in predicting 30-day mortality in adult patients hospitalized with COVID-19.
Methods: This work is a cohort study conducted between March 1 and April 30, 2020 in Ecuador.
Results: A total of 247 patients were included (mean age 60 ± 14 years, 70% men, overall mortality 41.3%). Patients with CURB-65 ≥ 2 had a higher mortality rate (57 vs. 17%, p < .001) that was associated with other markers of risk: advanced age, hypertension, overweight/obesity, kidney failure, hypoxemia, requirement for mechanical ventilation, or onset of respiratory distress.
Conclusions: CURB-65 ≥ 2 was associated with higher 30-day mortality on the univariate (Kaplan-Meier estimator) and multivariate (Cox regression) analysis.

Keywords: COVID-19; CURB-65; Coronavirus; Mortalidad; Mortality; Neumonía; Pneumonia; SARS-CoV-2.
 
Back
Top Bottom